Cargando…

Anesthetic management for a patient with myotonic dystrophy with remimazolam

BACKGROUND: Patients with myotonic dystrophy may have increased sensitivity to drugs used for anesthesia. We successfully managed general anesthesia in a patient with myotonic dystrophy using a novel intravenous anesthetic, remimazolam. CASE PRESENTATION: The patient was a 46-year-old man, 169 cm in...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Yasuhiro, Yoshimatsu, Aya, Yoshimura, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801543/
https://www.ncbi.nlm.nih.gov/pubmed/33432421
http://dx.doi.org/10.1186/s40981-021-00413-3
_version_ 1783635599492644864
author Morimoto, Yasuhiro
Yoshimatsu, Aya
Yoshimura, Manabu
author_facet Morimoto, Yasuhiro
Yoshimatsu, Aya
Yoshimura, Manabu
author_sort Morimoto, Yasuhiro
collection PubMed
description BACKGROUND: Patients with myotonic dystrophy may have increased sensitivity to drugs used for anesthesia. We successfully managed general anesthesia in a patient with myotonic dystrophy using a novel intravenous anesthetic, remimazolam. CASE PRESENTATION: The patient was a 46-year-old man, 169 cm in height, and weighing 60 kg. He was diagnosed with myotonic dystrophy 5 years previously. Phacoemulsification for both eyes was scheduled under general anesthesia. Anesthesia was induced with remimazolam 6 mg/kg/h for 1 min and maintained by continuous infusion at 0.25 mg/kg/h during surgery, a 1/4 dose of the standard infusion rate, as indexed by a bispectral index (BIS). Six minutes after remimazolam discontinuation, the patient opened his eyes on verbal command with sufficient spontaneous respiration. Flumazenil (0.2 mg) was administered to boost the patient’s recovery. CONCLUSION: In addition to the short-acting anesthetic remimazolam, the presence of the antagonist flumazenil enabled complete recovery from anesthesia, without postoperative complications.
format Online
Article
Text
id pubmed-7801543
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78015432021-01-21 Anesthetic management for a patient with myotonic dystrophy with remimazolam Morimoto, Yasuhiro Yoshimatsu, Aya Yoshimura, Manabu JA Clin Rep Case Report BACKGROUND: Patients with myotonic dystrophy may have increased sensitivity to drugs used for anesthesia. We successfully managed general anesthesia in a patient with myotonic dystrophy using a novel intravenous anesthetic, remimazolam. CASE PRESENTATION: The patient was a 46-year-old man, 169 cm in height, and weighing 60 kg. He was diagnosed with myotonic dystrophy 5 years previously. Phacoemulsification for both eyes was scheduled under general anesthesia. Anesthesia was induced with remimazolam 6 mg/kg/h for 1 min and maintained by continuous infusion at 0.25 mg/kg/h during surgery, a 1/4 dose of the standard infusion rate, as indexed by a bispectral index (BIS). Six minutes after remimazolam discontinuation, the patient opened his eyes on verbal command with sufficient spontaneous respiration. Flumazenil (0.2 mg) was administered to boost the patient’s recovery. CONCLUSION: In addition to the short-acting anesthetic remimazolam, the presence of the antagonist flumazenil enabled complete recovery from anesthesia, without postoperative complications. Springer Berlin Heidelberg 2021-01-12 /pmc/articles/PMC7801543/ /pubmed/33432421 http://dx.doi.org/10.1186/s40981-021-00413-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Case Report
Morimoto, Yasuhiro
Yoshimatsu, Aya
Yoshimura, Manabu
Anesthetic management for a patient with myotonic dystrophy with remimazolam
title Anesthetic management for a patient with myotonic dystrophy with remimazolam
title_full Anesthetic management for a patient with myotonic dystrophy with remimazolam
title_fullStr Anesthetic management for a patient with myotonic dystrophy with remimazolam
title_full_unstemmed Anesthetic management for a patient with myotonic dystrophy with remimazolam
title_short Anesthetic management for a patient with myotonic dystrophy with remimazolam
title_sort anesthetic management for a patient with myotonic dystrophy with remimazolam
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801543/
https://www.ncbi.nlm.nih.gov/pubmed/33432421
http://dx.doi.org/10.1186/s40981-021-00413-3
work_keys_str_mv AT morimotoyasuhiro anestheticmanagementforapatientwithmyotonicdystrophywithremimazolam
AT yoshimatsuaya anestheticmanagementforapatientwithmyotonicdystrophywithremimazolam
AT yoshimuramanabu anestheticmanagementforapatientwithmyotonicdystrophywithremimazolam